Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:
Listing of Claims:

Claims 1-5. (Cancelled)

6. (Currently Amended) A method for enhancing production of growth factor selected from the group consisting of

hepatocyte growth factor, nerve growth factor, epidermal growth factor, milk-derived growth factor, and insulin-like growth factor, the method comprising

administering a composition containing, as an active ingredient, a compound selected from the group consisting of 4,5-dihydroxy-2-cyclopenten-1-one of formula (I):

4-hydroxy-2-cyclopenten-1-one;

a compound of formula (II):

$$X_1$$
 Y_1
 X_1
 X_1

wherein a bond in the five-membered ring represented by a broken line means that the five-membered ring may be either a cyclopentene ring having a double bond or a saturated cyclopentane ring; in the case of a cyclopentene ring, X_1 is OH, Y_1 is =0 and Z_1 is H; on the other hand, in the case of a cyclopentane ring, X_1 is =0, Y_1 is OH and Z_1 is OH; W_1 is a residue in which a SH group is removed from cysteine or a peptide containing cysteine;

a compound of formula (III):

$$\begin{array}{c|c}
O & O \\
O & C \\
O & C \\
O & R_1
\end{array}$$
(III)

wherein R_1 and R_2 may be the same or different from each other, and are hydrogen, or an aliphatic, aromatic or aromatic aliphatic group;

- 3 -

a compound of formula (IV):

$$\begin{array}{c}
O \\
O \\
O \\
R_4
\end{array}$$
(IV)

wherein R_3 and R_4 may be the same or different from each other, and are hydrogen, or an aliphatic, aromatic or aromatic aliphatic group, provided that R_3 and R_4 are not simultaneously H;


a compound of formula (V)

$$X_2$$
 Y_2
 Z_2
 Y_2
 Y_3


wherein a bond in the five-membered ring represented by a broken line means that the five-membered ring may be either a cyclopentene ring having a double bond or a saturated cyclopentane ring; in the case of a cyclopentene ring, X_2 is OR_5 , Y_2 is =0 and Z_2 is H; on the other hand, in the case of a cyclopentane ring, X_2 is =0, Y_2 is OR_6 and Z_2 is OR_7 ; OR_7 ; OR_8 is OR_8 or OR_9 ; OR_8 is H, OR_9 is H, OR_9

aromatic aliphatic group, and R_9 , R_{11} and R_{13} may be H), provided that R_6 and R_7 are not simultaneously H; W_2 is a residue in which a SH group is removed from a cysteine or a peptide containing cysteine;

a compound of formula (VI):



wherein R_{14} is an aliphatic, aromatic or aromatic aliphatic group, and n is 0 or 1, provided that if n is 0, R_{14} is not H; a compound of formula (VII):



wherein W_3 is a residue in which a SH group is removed from cysteine or a peptide containing cysteine;

4-(9-adeninyl)-2-cyclopenten-1-one; and

4-(9-guaninyl)-2-cyclopenten-1-one,

to a person who is suffering from a condition selected from the group consisting of -cirrhosis, cholestasis in liver, chronic-nephritis, wound, senile dementia, Alzheimer's

disease, peripheral neuropathy, a cerebrovascular disease, apex of brain, a degenerative disease resulting from head injury, anesthetic intoxication, growth impairment, amyotrophic lateral sclerosis, and osteoporosis, and renal insufficiency,

wherein the amount of said active ingredient is above 10 $\mu g/kg/day$ and less than 200 mg/kg/day.

Claim 7. (Cancelled)

- 8. (Previously presented) The method according to claim 6, wherein the composition is a food or a drink.
- 9. (currently amended) A method for enhancing production of growth factor selected from the group consisting of

hepatocyte growth factor, nerve growth factor, epidermal growth factor, milk-derived growth factor, and insulin-like growth factor, the method comprising

administering a composition containing, as an active ingredient, a compound selected from the group consisting of 4,5-dihydroxy-2-cyclopenten-1-one of formula (I):

Appln. No. 09/890,875 Amd. dated February 22, 2005 Reply to Office Action of October 29, 2004

4-hydroxy-2-cyclopenten-1-one;

a compound of formula (III):

$$\begin{array}{c|c}
O & O \\
O & C \\
O - C - R_1
\end{array}$$

$$\begin{array}{c|c}
O & C \\
O & C \\
O & C
\end{array}$$

$$\begin{array}{c|c}
O & C \\
O & C
\end{array}$$

$$\begin{array}{c|c}
O & C \\
O & C
\end{array}$$


wherein R_1 and R_2 may be the same or different from each other, and are hydrogen, or an aliphatic, aromatic or aromatic aliphatic group;

a compound of formula (IV):

$$\begin{array}{c}
O \\
O \\
O \\
O \\
R_4
\end{array}$$
(IV)

wherein R_3 and R_4 may be the same or different from each other, and are hydrogen, or an aliphatic, aromatic or aromatic aliphatic group, provided that R_3 and R_4 are not simultaneously H_7 :

a compound of formula (V)



wherein a bond in the five membered ring represented by a broken line means that the five membered ring may be either a cyclopentene ring having a double bond or a saturated cyclopentane ring; in the case of a cyclopentene ring, X₂ is OR₅, Y₂ is =0 and Z₂ is H; on the other hand, in the case of a cyclopentane ring, X₂ is =0, Y₂ is OR₆ and Z₂ is OR₇, R₅ is R₈ or (CO) R₉, R₆ is H, R₁₀ or (CO) R₁₁; and R₈ is H, R₁₂ or (CO) R₁₃ (wherein R₈, R₉, R₁₀, R₁₁, R₁₂ and R₁₃ may be the same or different from each other, and are an aliphatic, aromatic or aromatic aliphatic group, and R₉, R₁₁ and R₁₃ may be H), provided that R₆ and R₇ are not simultaneously H; W₂ is a residue in which a SH group is removed from a cysteine or a peptide containing cysteine;

a compound of formula (VI):


$$O = \begin{pmatrix} O \\ O \\ C \end{pmatrix} = R_{14}$$
 (VI)

wherein R_{14} is an aliphatic, aromatic or aromatic aliphatic group, and n is 0 or 1, provided that if n is 0, R_{14} is not H;

- 8 -

wherein R_{14} is an aliphatic, aromatic or aromatic aliphatic group, and n is 0 or 1, provided that if n is 0, R_{14} is not H;

a compound of formula (VII):



wherein W_3 is a residue in which a SH group is removed from cysteine or a peptide containing cysteine;

4-(9-adeninyl)-2-cyclopenten-1-one; and

4-(9-guaninyl)-2-cyclopenten-1-one,

to a person who is suffering from hepatitis, <u>cirrhosis</u>, chronic nephritis or renal insufficiency,

wherein the amount of said active ingredient is above 10 $\mu g/kg/day$ and less than 200 mg/kg/day.

10. (previously presented) The method according to claim 9, wherein the composition is a food or a drink.